ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
May 18 2022 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster
will be presented at the Society for Investigative Dermatology
(SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland,
Oregon, that highlights unique immunological profiles of the
subdermal tunnels in hidradenitis suppurativa, and how these
profiles are differentiated with the stage of disease severity. The
findings support the Company’s plans to advance TAVNEOS® (avacopan)
into Phase III development for the treatment of patients with
Hurley Stage III (severe) hidradenitis suppurativa.
The poster titled, Spatial Transcriptomic Analysis of HS Skin
Lesions Reveals that Tunnels are Immunologically Active and
Activity Correlates with Disease Severity, will be presented as
part of Poster/Exhibit Hall Session 2 on Friday, May 20 between
4:30 PM– 6:30 PM PT.
Hidradenitis suppurativa (HS) is a chronic, disabling,
inflammatory skin disease characterized by neutrophil-rich
inflammatory nodules, abscesses, and tunnels (sinus tracts).
Complement dysregulation and neutrophil activation have been
implicated in the pathogenesis of HS. The complement 5a (C5a)
receptor (C5aR) is highly expressed on neutrophils and is a major
driver of the pro-inflammatory functions. Clinical assessment of
the severity of HS includes staging using the Hurley system, where
Hurley Stage III disease defines severe HS and Hurley Stage II
denotes a more moderate disease presentation.
At the SID 2022 Annual Meeting, ChemoCentryx will present data
that show a marked increase in dermal inflammation in severe Hurley
Stage III HS lesions compared to moderate Hurley II lesions. Genes
for proinflammatory cytokines, chemokines, neutrophil activation
factors, and B cells had higher expression in the severe compared
to moderate HS lesions. The spatial gradients of cytokine and
chemokine gene expression support the idea that more differentiated
tunnels in Hurley III disease are intensely immunologically active,
potentially contributing to ongoing active severe disease, rather
than merely remnant structures of prior disease.
TAVNEOS, a potent and specific inhibitor of human C5aR, was
previously evaluated in the Phase II AURORA clinical trial in
patients with moderate Hurley Stage II or severe Hurley Stage III
HS. The data now presented at the SID meeting support and extend
the Company’s earlier findings showing increased presence of C5a-
and C5aR-bearing cells in Hurley Stage III skin biopsies relative
to Hurley II samples, and also provide further mechanistic evidence
underpinning TAVNEOS’s efficacy in patients with severe HS after 12
weeks of treatment in the AURORA trial.
ChemoCentryx plans to meet with the FDA to discuss the Phase III
development of TAVNEOS in patients with Hurley Stage III (severe)
HS late in the second quarter, with the goal of initiating a Phase
III clinical trial in those patients in the second half of
2022.
About
TAVNEOS®
(avacopan)TAVNEOS (avacopan), approved by the FDA
as an adjunctive treatment of ANCA-associated vasculitis, is a
first-in-class, orally administered small molecule that employs a
novel, highly targeted mode of action in complement-driven
autoimmune and inflammatory diseases. While the precise mechanism
in ANCA vasculitis has not been definitively established, TAVNEOS,
by blocking the complement 5a receptor (C5aR) for the
pro-inflammatory complement system fragment known as C5a on
destructive inflammatory cells such as blood neutrophils, is
presumed to arrest the ability of those cells to do damage in
response to C5a activation, which is known to be the driver of ANCA
vasculitis. TAVNEOS’s selective inhibition of only the C5aR is
believed to leave the beneficial C5a pathway through the C5L2
receptor functioning normally.
ChemoCentryx is also developing TAVNEOS for the treatment of
patients with C3 glomerulopathy (C3G), severe hidradenitis
suppurativa (HS) and Lupus Nephritis (LN). The US Food and Drug
Administration granted TAVNEOS orphan drug designation for
ANCA-associated vasculitis and C3G. The European Commission has
granted orphan medicinal product designation for TAVNEOS for the
treatment of two forms of ANCA-associated vasculitis: microscopic
polyangiitis and granulomatosis with polyangiitis (formerly known
as Wegener's granulomatosis), as well as for C3G. TAVNEOS has not
been approved for indications discussed as in development, and the
safety and efficacy of those uses has not been established.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and
developing new medications for inflammatory and autoimmune diseases
and cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally administered
therapies. In the United States, ChemoCentryx markets TAVNEOS®
(avacopan), the first approved orally administered inhibitor of the
complement 5a receptor as an adjunctive treatment for adult
patients with severe active ANCA-associated vasculitis. TAVNEOS is
also in late-stage clinical development for the treatment of severe
hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G).
Additionally, ChemoCentryx has early-stage drug candidates that
target chemoattractant receptors in other inflammatory and
autoimmune diseases and in cancer. For more information about the
Company visit www.chemocentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For
more information, please see the Full Prescribing Information and
Medication Guide, available at TAVNEOS.com.
Forward-Looking Statements
ChemoCentryx cautions that statements included in this press
release that are not a description of historical facts are
forward-looking statements. Words such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements include the Company's
statements regarding the achievement of anticipated goals and
milestones, whether a development path forward will be established
for TAVNEOS in the treatment of severe hidradenitis suppurativa
(HS), the timing of initiating Phase III clinical development, and
whether TAVNEOS will be shown to be effective in the treatment of
severe HS in future clinical trials. The inclusion of
forward-looking statements should not be regarded as a
representation by ChemoCentryx that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the
ChemoCentryx business and other risks described in the Company's
filings with the Securities and Exchange Commission ("SEC").
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and ChemoCentryx undertakes no obligation to revise or update this
news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included under the heading "Risk Factors" in ChemoCentryx's
periodic reports filed with the SEC, including ChemoCentryx's
Annual Report on Form 10-K filed with the SEC on March 1, 2022, and
its other reports which are available from the SEC's website
(www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com)
under the heading "Investors." All forward-looking statements are
qualified in their entirety by this cautionary statement. This
caution is made under the safe harbor provisions of Section 21E of
the Private Securities Litigation Reform Act of 1995.
Contacts:
Investors:Bill Slattery, Jr.Vice President,
Investor Relations& Corporate
Communications650.210.2970bslattery@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024